Risk of herpes zoster in individuals on biologics, DMARDS and/or corticosteroids for autoimmune diseases: A systematic review and meta-analysis

Marra, Fawziah, Lo, Elaine, Kalashnikov, Viktor and Richardson, Kathryn ORCID: https://orcid.org/0000-0002-0741-8413 (2016) Risk of herpes zoster in individuals on biologics, DMARDS and/or corticosteroids for autoimmune diseases: A systematic review and meta-analysis. Open Forum Infectious Diseases, 3 (4). ISSN 2328-8957

Preview	PDF (Accepted manuscript) - Accepted Version Download (560kB) | Preview
Preview	PDF (Published_Version) - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (763kB) | Preview

Abstract

Background: Studies examining the risk of herpes zoster (HZ) associated with immunosuppressants, such as biologics, non-biological disease modifying agents (nbDMARDs) or corticosteroids, have generated conflicting results. Methods: We conducted a systematic literature search from Jan 1946 to Feb 2016. Search terms related to HZ, rheumatoid arthritis, psoriasis, psoriatic arthritis, systemic lupus erythematous or inflammatory bowel disease, biologics, nbDMARDS and corticosteroids were used. We included randomized controlled trials (RCTs) and observational studies reporting associations between immunosuppressants and HZ outcomes in adults. For RCTs, we used the Mantel-Haenszel fixed-effects model to estimate pooled odds ratios (OR) and 95% confidence intervals (CI) for HZ risk. For observational studies, adjusted ORs were pooled separately using random-effects inverse variance models. Findings: Data were pooled from 40 eligible RCTs (20,136 patients) and 19 observational studies (810,939 patients). Biologics were associated with a greater risk of HZ than control (RCTs: OR 1.71, 95% CI 1.11-2.64; Observational studies: OR OR 1.58, 95% CI 1.39-1.81). In RCTs, the OR of non-TNF blockers was 2.19 (95% CI 1.20-4.02), but that of TNF blockers was not significantly different from control. Increased risks of HZ with nbDMARDs (OR 1.21, 95% CI 1.15-1.28) and corticosteroids (OR 1.73, 95% CI 1.57-1.89) were observed in observational studies, but few RCTs examined these comparisons. Conclusions: Immunocompromized patients receiving biologics were associated with an increased risk of HZ. The risk is also increased with corticosteroids and nbDMARDs. These findings raise the issue of prophylaxis with zoster vaccine in patients initiating immunosuppressive therapy for autoimmune diseases.

Item Type:	Article
Additional Information:	© The Author 2016. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.
Uncontrolled Keywords:	herpes zoster,meta-analysis,dmards,biologics,autoimmune diseases,rheumatoid arthritis,immunocompromised,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School:	Faculty of Medicine and Health Sciences > School of Health Sciences
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Health Promotion Faculty of Science > Research Groups > Norwich Epidemiology Centre Faculty of Medicine and Health Sciences > Research Groups > Norwich Epidemiology Centre
Depositing User:	Pure Connector
Date Deposited:	24 Sep 2016 00:57
Last Modified:	20 Apr 2023 00:14
URI:	https://ueaeprints.uea.ac.uk/id/eprint/60318
DOI:	10.1093/ofid/ofw205

Downloads

Actions (login required)

View Item